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Highlights: 
 Xpert Ultra detects tuberculosis in children with a superior sensitivity compared to Xpert. 
 The sensitivity of Xpert Ultra is considerably lower in children than in adults.  
 The decreased specificity of Xpert Ultra warrants further investigations. 
 Xpert Ultra might improve speed and reliability of tuberculosis diagnosis in children. 
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Abstract 
Objectives: We evaluated the diagnostic performance of the novel next-generation Xpert 
MTB/RIF Ultra (Xpert Ultra) in comparison to Xpert MTB/RIF (Xpert) assay for the detection of 
paediatric pulmonary tuberculosis in high burden settings. 
Methods: From May 2011 to September 2012, children with suspected pulmonary tuberculosis 
were enrolled at two Tanzanian sites and sputum samples were examined using sputum smear, 
Xpert and culture.  Xpert Ultra was tested between January and June 2017 using sputum pellets, 
which had been stored at -80°C. The diagnostic accuracy of Ultra versus Xpert was determined 
using well-defined case definitions as reference standard. 
Results: In total, 215 children were included. The median age was 5.4 years, the HIV prevalence 
was 52% and 13% had culture-confirmed pulmonary tuberculosis. When only the first available 
sample of each patient was analysed, the sensitivity of Xpert Ultra was 64.3 % (95% CI: 44.1 to 
81.4) while that of Xpert was 53.6% (95%CI: 33.9 to 72.5). The specificity of Xpert Ultra based on 
analysis of all available samples was 98.1% (95%CI: 93.4 to 99.7), that of Xpert was 100%. 
Conclusions:  Xpert Ultra was found to have a higher sensitivity, but slightly reduced specificity 
compared to Xpert in detecting pulmonary tuberculosis in children.   
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Introduction 
The World Health Organisation (WHO) estimated one million new tuberculosis (TB) cases and 
250,000 TB-related deaths among children younger than 15 years in 2016 1. Childhood TB is often 
underdiagnosed and underreported due to suboptimal diagnostic methods and weak national 
reporting systems 2,3.  Microbiological confirmation is rare, because of difficulties in obtaining 
adequate samples from children, the low bacillary loads and missing host biomarker 4. 
Consequently, the diagnosis of paediatric TB in most high TB burden settings  is based on clinical 
symptoms, TB contact information and, if available, chest radiography 5,6.  
The Xpert MTB/RIF assay (Xpert; Cepheid Inc., Sunnyvale, CA, USA) enables detection of both 
Mycobacterium tuberculosis (MTB) complex and rifampicin resistance in pulmonary and 
extrapulmonary samples. Since 2013, the WHO strongly recommends the assay as a first 
diagnostic test in children suspected of having MDR-TB or HIV-associated TB while a conditional 
recommendation is made for all children suspected of having TB 7. Unfortunately, the 
expectations for substantially improved TB detection in children are only partly met.  According 
to a recent meta-analysis, Xpert has a suboptimal sensitivity of 62% in expectorated or induced 
sputum samples compared to culture 8.  
The novel Xpert MTB/RIF Ultra assay (Xpert Ultra; Cepheid Inc., Sunnyvale, CA, USA) has been 
developed to overcome the shortcomings of Xpert with regard to limited sensitivity for MTB 
complex detection in patients with paucibacillary disease 9 and occasionally false-positive and -
negative signals for rifampicin resistance 10,11. Xpert Ultra is equipped with two additional 
molecular targets (IS6110 and IS1081), a larger chamber for DNA amplification, fully  nested  
nucleic  acid  amplification,  faster  thermal  cycling,  and  improved assay chemistry 12. These 
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technical improvements result in a lower limit of detection of the MTB H37Rv strain in sputum of 
15.6 CFU/ml for Xpert Ultra versus 112.6 CFU/ml for Xpert 12. 
A prospective, multicentre, diagnostic accuracy study in adults demonstrated a higher sensitivity 
of Xpert Ultra compared to Xpert in clinical use, especially for paucibacillary samples (i.e. from 
patients with smear-negative TB and/or HIV infection). However, the increased sensitivity comes 
at the cost of decreased specificity 13. In 2017, the WHO declared Xpert Ultra non-inferior to 
Xpert and gave guidance on the interpretation of Xpert Ultra semi-quantitative ‘trace’ results 
which are considered the main reason for the reduced specificity and often represent non-viable 
bacilli particularly in patients with a recent history of TB 14.  
Data on the diagnostic performance of Xpert Ultra in children are scarce. We conducted a 
comparative diagnostic accuracy study of Xpert Ultra versus Xpert for the detection of pulmonary 
TB and rifampicin resistance in children suspected of having TB.  
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Methods 
Study population and case definition categories 
This diagnostic accuracy study was performed at two Tanzanian research sites, the NIMR-Mbeya 
Medical Research Center, Mbeya, and the Ifakara Health Institute, Bagamoyo in accordance with 
STARD guidelines (Supplementary table 1) 15.  From May 2011 to September 2012, children 
suspected of having TB, between six months and 16 years of age were consecutively enrolled and 
followed up to a maximum of nine months. At least one of the following eligibility criteria had to 
be met:  i) persistent, non-remitting cough of more than 14 days not responding to antibiotics, ii) 
repeated episodes of fever within the last 14 days not responding to antibiotics, after malaria has 
been excluded, ii) weight loss or failure to thrive during the previous three months, iv) signs and 
symptoms suggestive of extrapulmonary TB. Children who had received anti-TB treatment in the 
past 12 months were excluded. 
Based on clinical examinations and microbiological evaluations of all available sputum samples, 
children were classified into five groups: culture confirmed TB (at least one sputum sample was 
culture-positive for MTB), highly probable TB (chest radiograph consistent with TB confirmed by 
two independent reviewers, histology/cytology typical for TB, or fluorescent/acid-fast bacilli on 
microscopy), probable TB (clinically suspected TB without objective findings as above),  “not TB” 
(alternative diagnosis established and clinical resolution without anti-TB treatment),  unknown TB 
status (any other possible combination of results and/or loss 
to follow up after recruitment) 16. 
 
Clinical and Laboratory Procedures 
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Demographic information and results of medical history, clinical examination, anthropometric 
measurements, HIV testing, CD4+ T cell count, tuberculin skin test, and chest radiography, 
assessed by two independent experts, were recorded at enrolment. The study protocol 
scheduled for collection of at least two induced or three expectorated sputum samples. 
However, in some cases the type and also the number of sputum samples collected varied 
between one and five according to clinical requirements. 
After decontamination with N-acetyl-L-cysteine-sodium hydroxide (NALC-NaOH), all sputum 
sample pellets were examined by light microscopy after Ziehl-Neelsen staining. The pellet of at 
least one sample was inoculated into liquid (MGIT; BACTEC MGIT 960, Becton Dickinson, USA) 
and onto solid Loewenstein-Jensen (LJ) culture media. Cultures positivity for growth of acid-fast 
bacilli was confirmed by MPT64 antigen or molecular tests (Genotype MTBC or CM, Hain 
Lifescience, Germany). Phenotypic (DST in MGIT using SIRE kit) and genotypic (MTBDRplus, Hain 
Lifescience, Germany) tests were applied for drug resistance testing.  Xpert was used to test at 
least one of the child’s sputum samples.  
Xpert Ultra testing was performed between 7th January and 25th July 2017 at both sites using 
decontaminated sputum pellets which were stored at -80°C. At least one sample from each 
participant with the TB classification culture confirmed, highly probable, probable, or “not TB” 
was assigned to Xpert Ultra testing. Only a randomly selected sub-group with unknown TB status 
was analysed due to cost restrictions.  The GeneXpert instruments provided automated readouts 
for detection of MTB complex (detected, not detected, or error message) and rifampicin 
resistance (detected, not detected, or indeterminate). Semi-quantitative results for Xpert Ultra 
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were recorded as follows: trace, very low, low, medium, or high. All laboratory tests were 
performed blinded to information about clinical course and/or case definition categories. 
 
Statistical Analysis 
Xpert Ultra results were retrieved from the machine export files. All other data were double 
entered into Microsoft Access databases (Microsoft Corp, Redmond, WA), compared and 
corrected for data entry errors. All statistical analyses were performed using Stata (version 15.1, 
StataCorp, College Station, TX). 
To characterize the study population, we report percentages for categorical variables and 
medians and interquartile ranges for continuous variables, since none of them was normally 
distributed. Calculation of diagnostic parameters (sensitivity, specificity, positive and negative 
predictive value) of the tests only included children with culture confirmed TB and children 
where TB was excluded (“not TB”), respectively. This reference standard is based on all available 
culture results for each child, including samples which were not available for Xpert Ultra testing, 
whereas the calculation of diagnostic accuracy in this article are only based on samples that were 
Ultra tested. Diagnostic accuracy parameters were calculated in three ways: 1. Per patient/1st 
sample, including only the first available sample tested with Ultra; 2. Per patient/all samples, 
including all samples tested with Ultra for each patient and regarding the patient as test positive 
if any of these samples was positive; 3. Per sample, including all tested samples individually with 
Ultra. Exact (Clopper-Pearson) 95% confidence intervals were calculated and were adjusted for 
within person clustering in the per sample analysis. 
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To examine the potential influence of other factors (HIV status, gender, age etc.) on Xpert Ultra 
sensitivity, we performed log-binomial regression adjusted for within person clustering 17. 
 
Ethical Approval and Informed Consent 
The study protocol was approved by the Mbeya Medical Research and Ethics Committee, the 
Institutional Review Board of the Ifakara Health Institute, and the Medical Research Coordinating 
Committee of Tanzania. Written informed consent was obtained from a literate parent or legal 
guardian, including consent to store samples for future diagnostic evaluation. In case of illiteracy, 
informed oral consent was attested by an independent witness. Children older than seven years 
of age additionally provided assent for participation. 
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Results 
In total, 293 children were enrolled at the two sites. Subsequently, 16 children were excluded 
from the analysis due to lack of stored sputum (n=12), the participants died during enrolment 
(n=2) or the children had solely extrapulmonary TB (n=2). Another 62 participants were excluded 
because of their unknown TB status. Thus, 215 children were included for analysis of the Xpert 
Ultra diagnostic performance. The STARD diagram shows the flow of participants according to 
Xpert Ultra results and case definition categories (Figure 1).   
Overall, 13% (28/215) of the children had culture confirmed, 4 % (9/215) highly probable, 24 % 
(52/215) probable and 50% (107/215) “not TB”. Furthermore, 9% (19/215) belonged to the 
unknown TB status group.  The median age was 5.4 years (IQR, 1.5 to 9.9). The overall HIV 
prevalence was 52 % (110/212). The highest HIV prevalence was found in the probable TB and 
the unknown TB status classification group amounting to 77% (40/52) and 71% (12/17), 
respectively. According to the WHO immunological classification, severe immunodeficiency was 
found in 40% (42/105) of the HIV-infected children. Detailed demographic and clinical 
characteristics are presented in table 1.   
Xpert Ultra testing was performed on 520 sputum samples with 517 valid results (Supplementary 
figure 1). Corresponding results for culture (MGIT and/or LJ), smear microscopy and Xpert were 
available in 98% (505/517), 98% (506/517) and 81% (417/517), respectively. The proportion of 
samples with valid Xpert Ultra, Xpert and culture (MGIT and/or LJ) results is shown in 
Supplementary table 2. The Xpert Ultra assay was positive in 43 samples from 24 patients. In 
these samples, Xpert Ultra showed either a negative (33/43) or an indeterminate (10/43) result 
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for rifampicin resistance. Of the 28 samples that were MTB positive in both Xpert and Xpert Ultra 
testing, 25 were not RIF resistant in both tests, and three were not resistant in the Xpert, but 
indeterminate in the Ultra. 
Per patient sensitivity and specificity analyses used the categories culture confirmed and “not TB” 
as reference standard. Taking only the first available sputum sample into account, the sensitivity 
of Xpert Ultra was 64.3 % (95% CI: 44.1 to 81.4), while the sensitivity amounted to 75.0% (95%CI: 
55.1 to 89.3) when all samples tested by Xpert Ultra were included into the analysis (Table 2). In 
comparison, per patient sensitivity for Xpert and smear microscopy was 53.6% (95%CI: 33.9 to 
72.5) and 35.7% (95%CI: 18.6 to 55.9) when test results from only the first sample was used and 
60.7% (95%CI: 40.6 to 78.5) and 42.9% (95%CI: 24.5 to 62.8) when test results from all samples 
were included. The specificity of Ultra based on the analysis of the first available sample was 
100.0% (95%CI: 96.6 to 100) and based on all available samples it decreased to 98.1% (95%CI: 
93.4 to 99.7), whereas Xpert and smear had a specificity of 100% in both scenarios (Table 2). 
Xpert Ultra was positive in three study participants without culture confirmed TB. Firstly, a trace-
positive Xpert Ultra result was recorded in one sputum sample of a one-year old HIV-positive boy 
with probable TB who received anti-TB treatment based on clinical suspicion. Secondly, a 
negative Xpert, but a high positive Xpert Ultra result was found in a nine-year old, HIV-positive 
girl with a history of TB at the age of six. The girl was diagnosed with bronchitis at enrolment and 
showed no clinical signs of TB at month 5 and 9 follow up visits. Finally, a trace result was found 
in an 11-year-old HIV-negative boy who was finally diagnosed of having asthma. The latter two 
study participants had been classified as having “not TB”. 
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A stratified analysis showed that both Xpert Ultra and Xpert had a higher sensitivity in HIV-
positive than HIV-negative children; this difference was not statistically significant. Both Xpert 
Ultra and Xpert had a higher sensitivity in children with smear-positive compared to children with 
smear-negative TB. The difference in sensitivity between Xpert Ultra and Xpert was highest 
within the HIV-positive subgroup (88.9% vs. 66.7%) followed by the smear-negative subgroup 
(44.4% vs. 27.8%) (Table 3).  
Associations between Xpert Ultra sensitivity and different potential predictors were assessed in 
uni- and multivariable regression models. Only HIV-positivity was significantly associated with 
Xpert Ultra sensitivity in the multivariable model (Supplementary table 3).  
Per sample sensitivity within the group of culture confirmed TB cases showed a sensitivity of 
64.3% for Xpert Ultra and 53.6% for Xpert, while the sensitivity for LJ and MGIT combined was 
75.0% when only the first collected sample was included. (Supplementary table 4).  A head-to-
head comparison of results for samples which were tested by all diagnostics (n=407), i.e. Xpert 
Ultra, Xpert, smear microscopy and culture (MGIT and/or LJ), showed that Xpert Ultra identified 
TB in seven Xpert negative samples belonging to four different children who were all smear 
negative, and in three culture negative samples. Culture was the only positive test in 12 samples 
and smear in one sample (Figure 2). 
The semi-quantitative readout for positive Xpert Ultra samples was as follows: 12% high, 49% 
medium, 5% low, 14% very low and 21% trace. These results agreed well with the semi 
quantitative results of Xpert (Supplementary table 5).  
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Discussion 
Our data show a higher sensitivity of Xpert Ultra (64.3%) compared to Xpert (53.6%) in children 
with culture confirmed TB. This is in line with a recent publication, where 67.5% of TB culture 
positive children were detected by Xpert Ultra with a difference in sensitivity between Xpert 
Ultra and Xpert of maximal 10%, depending on the reference standard 18. In our study, as in an 
earlier multicentre diagnostic study in adults 13, the difference in sensitivity among these two 
tests was especially pronounced in smear-negative children, with 44.4% for Xpert Ultra versus 
27.8% for Xpert. Compared to Xpert, the new Xpert Ultra detected four additional TB cases, three 
children with the first available sample and a fourth case if all available sputa were tested. All 
additional TB cases were smear-negative.  
The improved sensitivity of Xpert Ultra might not only lead to larger proportion of confirmed 
childhood TB cases but also to earlier TB diagnosis and treatment initiation particularly compared 
to culture-based algorithms. Importantly, in the per sample analysis the sensitivity of Xpert Ultra 
was similar to that of solid culture (64.3%) and only moderately lower compared to liquid and 
solid culture combined (75.0%) when only one sample per child was tested. Further, as the 
reference standard for culture confirmed TB was based on up to five sputum culture results, 
which even includes sputa that could not be Ultra tested, the overall diagnostic sensitivity of 
Xpert Ultra versus culture might be underestimated as a maximum of only four samples per child 
were tested with Xpert Ultra. Our data suggest that the overall sensitivity of Xpert Ultra increases 
with the number of sputum samples tested. This could not be sufficiently analysed because 
second, third or fourth samples were unavailable for many children. Though, the performance of 
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only one Ultra test is most realistic for resource-poor settings considering the cost of about 10 
USD per test cartridge.  
Although the sensitivity of Xpert Ultra was higher than that of smear and Xpert, Xpert Ultra did 
not detect TB among children with highly probable TB.  Like other microbiological tests, Xpert 
Ultra depends on the presence of mycobacteria in the diagnostic sample. Due to the 
paucibacillary nature of pulmonary TB in children, sputum samples are often no ideal specimen 
for TB diagnosis 19,20. Further paediatric studies are needed to evaluate the diagnostic 
performance of Xpert Ultra in alternative specimens as blood, stool or cerebrospinal fluid. The 
poor performance of all assays in the highly probable TB group underlines the relevance of 
systematic clinical investigations and medical expertise for the diagnosis childhood TB and also 
calls for novel sputum-independent tests for paediatric TB [4,20–22]. 
The presence of false-positive Xpert Ultra results among three children with no culture confirmed 
TB might constitute a further challenge to TB diagnosis in clinical routine.  As in adults 13, the 
specificity of Xpert Ultra (98.1%) was reduced compared to Xpert (100%) in our study, but only 
when all available samples were included in the specificity analysis. One child in the probable TB 
group might have been correctly identified as an active TB case only by Xpert Ultra. In a second 
child, who was classified as “not TB” but had been treated for TB three years ago, Xpert Ultra 
might have detected MTB DNA only as remnant of a previous active TB episode 14,24. However, 
cross-contamination or sample mix-up cannot be excluded. In a third child the false “trace” 
detection of TB by Xpert Ultra cannot be explained.  
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Thus, the specificity of Xpert Ultra compared to culture was higher in our paediatric compared to 
an adult study 13, most likely because the proportion of participants with a history of TB was 
much smaller (7% versus 21%). To increase specificity, Dorman et al. 13 discussed scenarios for re-
classification of Xpert Ultra trace results in adults. In our study, nine samples had a trace-positive 
Xpert Ultra result. Seven were collected from children with confirmed TB, one belonged to a child 
with probable, but clinically diagnosed TB, and only one to a child with “not TB”. Moreover, the 
only child with history of TB who was incorrectly detected by Xpert Ultra had a high-positive, not 
a trace-positive result. Consequently, reclassifying all trace-positive results as TB-negative cannot 
be recommended.  
We observed a substantial difference in sensitivity of more than 22% between Xpert Ultra and 
Xpert in the HIV-positive children. This can be explained by the reduced limit of detection of 
Xpert Ultra which is especially relevant for paucibacillary TB in HIV-positives. The sensitivity of 
Xpert Ultra was remarkably higher in HIV-positive (88.9%) versus HIV-negative TB cases (52.6%). 
This seems counterintuitive and can only be explained by a study-specific composition of the 
group with culture confirmed TB, e.g. the proportion of smear-positives was higher in HIV-
positive children than in HIV-negative children. In the previous Xpert Ultra studies 13,18 and earlier 
Xpert studies in children 16,25 no statistically significant difference in the performance of Xpert 
Ultra and Xpert among HIV-positive and -negative TB suspects was found. 
Sub-optimal sensitivity M. tuberculosis culture undermines its suitability as a reference standard 
in paediatric diagnostic accuracy studies. Therefore, we have to assume -with high degree 
uncertainty- that the sensitivity of Ultra in our study would be in fact lower, if clinical and 
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radiological along with microbiological criteria are applied to define the reference standard. 
Further limitations of our study include the small number of participants with confirmed TB 
which may have led to less accurate estimates for diagnostic performance parameters, especially 
in subgroups analyses. The exclusion of children with unknown TB might have hypothetically 
introduced selection bias. The retrospective approach of Xpert Ultra evaluation, using a limited 
sub-set of stored sputum samples, may have hampered the detection of MTB by Xpert Ultra. 
Although it seems that Xpert Ultra can reliably detect also small amounts of DNA in sputum 
samples even from dead bacteria 12,13, it is not known yet how the decontamination process with 
NALC-NaOH as well as the long term storage at -80°C influences the performance of the test. 
Also, we were not able to assess the detection of rifampicin resistance as all strains were drug-
susceptible.  
In summary, this study demonstrated a higher sensitivity of Xpert Ultra compared to Xpert in 
children. When only one sample per child was tested, Xpert Ultra found three additional TB 
cases, the majority of them with trace-positive Ultra results. The reduction in specificity of Xpert 
Ultra seems to be less pronounced in children than in adults. Xpert Ultra thus has the potential to 
increase the reliability and speed of TB diagnosis in children from settings with a high burden of 
TB.  
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Table 1: Demographics and clinical characteristics of study participants by classification group 
 
Culture 
confirmed 
TB 
Highly  
probable 
TB 
Probable 
TB Not TB 
Unknown  
TB status 
All 
Children 
N children  
(N samples with valid Ultra 
results) 28 (69) 9 (20) 52 (139) 107 (270) 19 (19) 215 (517) 
Age 
Median years (IQR) 
5.7 (1.9; 
10.2) 
7.9 (2.2; 
11.8) 4.1 (1.3; 9.7) 
6.0 (2.0; 
10.2) 
3.2 (1.0; 
11.1) 5.4 (1.5; 9.9) 
Gender 
Female, n/N (%) 13/28 (46) 6/9 (67) 23/52 (44) 53/107 (50) 8/19 (42) 103/215 (48) 
HIV status 
Negative HIV test, n/N (%) 19/28 (68) 4/9 (44) 12/52 (23) 62/106 (58) 5/17 (29) 102/212 (48) 
Positive HIV test, n/N (%) 9/28 (32) 5/9 (56) 40/52 (77) 44/106 (42) 12/17 (71) 110/212 (52) 
No data, n 0 0 0 1 2 3 
Antiretroviral treatment 
On ART at enrolment, n/N (%) 3/7 (43) 2/5 (40) 15/31 (48) 13/32 (41) 6/11 (55) 39/86 (45) 
Not on ART at enrolment, n/N 
(%) 
4/7 (57) 3/5 (60) 16/31 (52) 19/32 (59) 5/11 (45) 47/86 (55) 
No data, n 2 0 9 12 1 24 
Immune suppression status of 
HIV-positive children 
No suppression, n/N (%) 3/8 (38) 0/5 (0) 13/37 (35) 18/43 (42) 2/12 (17) 36/105 (34) 
Mild suppression, n/N (%) 0/8 (0) 1/5 (20) 3/37 (8) 6/43 (14) 1/12 (8) 11/105 (10) 
Moderate suppression, n/N (%) 2/8 (25) 0/5 (0) 6/37 (16) 5/43 (12) 3/12 (25) 16/105 (15) 
Severe suppression, n/N (%) 3/8 (38) 4/5 (80) 15/37 (41) 14/43 (33) 6/12 (50) 42/105 (40) 
No data, n 1 0 3 1 0 5 
Weight for age (< 10 years 
only) 
Median Z score (IQR) 
-2.2 (-3.9; -
1.4) 
-2.5 (-4.5; -
1.9) 
-2.9 (-3.9; -
1.8) 
-2.0 (-3.0; -
0.9) 
-3.1 (-4.3; -
1.1) 
-2.5 (-3.7; -
1.2) 
Height for age  
Median Z score (IQR) 
-2.8 (-3.7; -
1.8) 
-3.3 (-3.6; -
1.3) 
-3.4 (-4.1; -
1.9) 
-1.9 (-3.1; -
0.8) 
-3.4 (-4.1; -
2.2) 
-2.5 (-3.6; -
1.4) 
Weight for height (<120 cm 
only) 
Median Z score n (IQR) 
-1.6 (-2.9; -
0.7) 
-2.3 (-4.4; -
0.8) 
-1.3 (-2.6; -
0.3) 
-1.3 (-2.1; -
0.3) 
-1.7 (-2.4; -
0.3) 
-1.4 (-2.3; -
0.4) 
Body mass index for age  
Median Z score (IQR) 
-1.7 (-2.7; -
0.8) 
-2.7 (-4.4; -
1.5) 
-1.3 (-2.3; -
0.3) 
-1.3 (-2.1; -
0.4) 
-1.7 (-3.4; -
0.8) 
-1.4 (-2.5; -
0.5) 
Tuberculin skin test 
Positive in HIV-negative 
children, n/N (%) 13/18 (72) 1/4 (25) 2/12 (17) 10/59 (17) 1/5 (20) 27/98 (28) 
Positive in HIV-positive 
children, n/N (%) 5/9 (56) 0/5 (0) 6/37 (16) 2/40 (5) 0/12 (0) 13/103 (13) 
Positive + indeterminate HIV 
test, n/N (%) 0/0 0/0 0/0  0/0  0/1 (0) 0/1 (0) 
No data, n 1 0 3 8 1 13 
TB contact in last 12 months 
Yes, n/N (%) 12/26 (46) 2/7 (29) 14/46 (30) 28/99 (28) 3/16 (19) 59/194 (30) 
No, n/N (%) 14/26 (54) 5/7 (71) 32/46 (70) 71/99 (72) 13/16 (81) 135/194 (70) 
Unknown, n 2 2 6 8 3 21 
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Table 2: Per patient diagnostic accuracy in the culture confirmed TB and “not TB” groups (n-positive or 
n-negative = number of patients tested positive or negative. N = number of patients tested, PPV= 
Positive Predictive Value, NPV = Negative Predictive Value).  
 
  
 Sensitivity 
 
 % (95 % CI), n-
positive/N 
Sampl
es 
per 
patient 
Mean 
(SD) 
Specificity 
 
% (95 % CI), n-
negative/N 
Samples 
per 
patient 
Mean 
(SD) 
PPV 
 
% (95 % CI) 
NPV 
 
% (95 % CI) 
Xpert Ultra       
First available 
sample 
64.3 (44.1 to 81.4),  
18/28 
1 
100.0 (96.6 to 100.0), 
107/107 
1 
100.0 (81.5 to 
100.0) 
91.5 (84.8 to 
95.8) 
All samples 
75.0 (55.1 to 89.3),  
21/28 
2.46 
(0.74) 
98.1 (93.4 to 99.7), 
105/107 
2.52 
(0.69) 
91.3 (72.0 to 
98.9) 
93.8 (87.5 to 
97.6) 
Xpert        
First available 
sample 
53.6 (33.9 to 72.5), 
15/28 
1 
100.0 (96.5 to 100.0), 
105/105 
1 
100.0 (78.2 to 
100.0) 
89.0 (81.9 to 
94.0) 
All samples 
60.7 (40.6 to 78.5), 
17/28 
2.11 
(0.92) 
100.0 (96.5 to 100.0), 
105/105 
1..90 
(0.93) 
100.0 (80.5 to 
100.0) 
90.5 (83.7 to 
95.2) 
Smear 
microscopy 
      
First available 
sample 
35.7 (18.6 to 55.9), 
10/28 
1 
100.0 (96.6 to 100.0), 
107/107 
1 
100.0 (69.2 to 
100.0) 
85.6 (78.2 to 
91.2) 
All samples 
42.9 (24.5 to 62.8), 
12/28 
2.39 
(0.74) 
100.0 (96.6 to 100.0), 
107/107 
2.47 
(0.68) 
100.0 (73.5 to 
100.0) 
87.0 (79.7 to 
92.4) 
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Table 3: Per patient sensitivity of Ultra and Xpert in children with culture confirmed TB, stratified by 
HIV-status and smear result (n-positive = number of patients tested positive. N = number of patients 
tested).  
 
 
 Sensitivity Ultra 
1
st
 available sample 
 % (95 % CI), n-positive/N 
Sensitivity Xpert 
1
st
 available sample 
 % (95 % CI), n-positive/N 
HIV-negative 52.6 (28.9 to 75.6), 10/19 47.4 (24.4 to 71.1), 9/19 
HIV-positive 88.9 (51.8 to 99.7), 8/9 66.7 (29.9 to 92.5), 6/9 
Sensitivity difference 36.3 (5.8 to 66.7) 19.3 (-18.8 to 57.4) 
   
Smear-negative 44.4 (21.5 to 69.2), 8/18 27.8 (9.7 to 53.5), 5/18 
Smear-positive 100.0 (69.2 to 100.0), 10/10 100.0 (69.2 to 100.0), 10/10 
Sensitivity difference 55.6 (32.6 to 78.5) 72.2 (51.5 to 92.9) 
 
 
